Abstract. Steroids synthesized in the periphery or de novo in the brain, so called 'neurosteroids', exert both genomic and nongenomic actions on neurotransmission systems. Through rapid modulatory effects on neurotransmitter receptors, they influence inhibitory and excitatory neurotransmission. In particular, progesterone derivatives like 3α-hydroxy-5α-pregnan-20-one (allopregnanolone) are positive allosteric modulators of the γ-aminobutyric acid type A (GABA A ) receptor and therefore act as inhibitory steroids, while pregnenolone sulphate (PREGS) and dehydroepiandrosterone sulphate (DHEAS) are negative modulators of the GABA A receptor and positive modulators of the N-methyl-D-aspartate (NMDA) receptor, therefore acting as excitatory neurosteroids. Some steroids also interact with atypical proteins, the sigma (σ) receptors. Recent studies particularly demonstrated that the σ 1 receptor contributes effectively to their pharmacological actions. The present article will review the data demonstrating that the σ 1 receptor binds neurosteroids in physiological conditions. The physiological relevance of this interaction will be analyzed and the impact on physiopathological outcomes in memory and drug addiction will be illustrated. We will particularly highlight, first, the importance of the σ 1 -receptor activation by PREGS and DHEAS which may contribute to their modulatory effect on calcium homeostasis and, second, the importance of the steroid tonus in the pharmacological development of selective σ 1 drugs.
Neurosteroids and σ receptors
The first description of a biological activity for steroids, the anesthetic properties of progesterone, dates from the 1941 report by Selye (1) . The subsequent characterization of central effects exerted by steroid hormones, and their syntheses in the nervous system defining the concept of neurosteroids, dates from 25 years ago. Neuroactive steroids include both steroids from the periphery, which are transported through the blood-brain-barrier and act within the brain, and locally synthesized neurosteroids. Their physiological actions, demonstrated from embryogenesis through adult life, involve genomic actions, mediated by steroid receptors translocating into the nucleus, and non-genomic neuromodulatory actions affecting directly several ion channels, neurotransmitter receptors, and second messenger systems. The syntheses and effects of these neuro (active)steroids and their physiopathological consequences have been extensively reviewed (2 -13) . In particular, the mechanisms by which they act as allosteric modulators of the γ-aminobutyric acid type A (GABA A ) receptor and N-methyl-D-aspartate (NMDA) type of glutamate receptor is now extensively documented. They also affect acetylcholine systems through direct and indirect actions. More atypical is their reported interaction with the sigma 1 (σ 1 ) receptors (14 -17) . In the present review article, we will detail the molecular, physiological, and behavioral data supporting the concepts that not only certain neurosteroids interact at physiological concentration with σ 1 receptors and may represent their endogenous ligands but also that the neurosteroid / σ 1 receptor interaction may present major physiopathological consequences. We will particularly illustrate their involvement in memory processes and vulnerability to drug addiction.
Neuro(active)steroids biosyntheses
Steroids are synthesised in adrenal glands and gonads and exert their hormonal effects in peripheral organs and the brain. The identification of pools of steroids whose levels were higher in the brain than in plasma, independently of peripheral sources led to the concept of 'neurosteroids' (18 -20) . These neurosteroids are synthesized locally in the mitochondria of glial cells, such as oligodendrocytes and astrocytes, and neurons. Fifteen days after removing the sources of circulating steroids by adrenalectomy and gonadectomy (AdX / CX) in rodents, no difference in the brain neurosteroid levels could be measured as compared to non-operated animals (18, 19, 21) . Cholesterol is transported into the mitochondrion by the peripheral type of benzodiazepine receptor and then converted into pregnenolone (PREG) by a cytochrome P450 side-chain cleavage (P450scc) enzyme, a conversion that constitutes the rate-limiting step in steroidogenesis (3) . PREG could then be metabolized into progesterone by a 3β-hydroxysteroid dehydrogenase (3βHSD). PREG could also be converted into 17α-hydroxypregnenolone by a cytochrome P450c17, which leads to dehydroepiandrosterone (DHEA) and androstenedione by the scission of the c17,20 bond. These two pathways lead to the formation of pregnanes and androstanes steroids, respectively, and the most highly expressed steroids in the brain are PREG, DHEA, their sulphate esters (PREGS and DHEAS), progesterone, and 3α-hydroxy-5α-pregnan-20-one (allopregnanolone) among the tetrahydroprogesterone isomers. The expression, distribution, and ontogeny of most of the steroidogenic enzymes and synthesized steroids have been determined in the brain (3) and similarities with the peripheral synthetic pathway were identified. Most of the enzymes, including P450scc, P450c17, 3βHSD, and 5α-reductase, which convert PREG into progesterone, are co-expressed in limbic structures such as the hippocampus, caudate putamen, hypothalamic nuclei, cortex, olfactory bulb, and cerebellum (3) .
Various physiological and pathological conditions are associated with changes in neurosteroid levels. Neurosteroid syntheses significantly vary during acute and chronic stress, pregnancy, neural development, and normal and pathological aging. In humans, plasma levels of DHEAS decline with age (22, 23) . In rodents, significant decreases of PREGS levels in aged Sprague Dawley rat brain were reported to correlate with impaired memory functions (24) . Aged C57BL / 6 mice or senescence-accelerated (SAM) mice also show important decreases in the brain levels of PREG and PREGS (PREG/ S), DHEA and DHEAS (DHEA / S), or progesterone (25, 26) . Moreover, brain structural abnormalities related to Alzheimer's disease, like both β-amyloid deposits and neurofibrillary tangles, which result from the aggregation of pathologic τ proteins, affect brain neurosteroid levels. Brown et al. (27) reported that β 1-42 -amyloid protein increased DHEA levels in a human glia-derived cell line, after a 24 h application, a synthesis interpreted as a neuroprotective response to the β-amyloid-induced toxicity. Neurosteroid levels were measured in two in vivo models of β-amyloid toxicity, the intracerebroventricular injection of aggregated β [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] -amyloid peptide in mice and the chronic infusion during a 2-week period of β 1-40 -amyloid protein in rats. Decreased levels of PREG / S, DHEA / S, and progesterone were identified in the hippocampus, cortex, and cerebellum as compared to the control animals (28, 29) . Neurosteroid levels were also measured post-mortem in individual brain regions of Alzheimer's disease patients and aged non-demented controls, including the hippocampus, amygdala, frontal cortex, striatum, hypothalamus, and cerebellum (30) , supporting a general trend towards decreased levels of all steroids observed in brain regions of Alzheimer's disease patients compared to controls. PREGS levels were also significantly lower in the striatum, and cerebellum, as were DHEAS levels in the hypothalamus, striatum, and cerebellum. In contrast, progesterone and allopregnanolone levels were reduced, but non-significantly, brain structures, including the hypothalamus, striatum, frontal cortex, or amygdala. Finally, a significant negative correlation was found between the levels of cortical β-amyloid peptides and those of PREGS in the striatum and cerebellum and between the levels of phosphorylated τ proteins and DHEAS in the hypothalamus (30) . Since high levels of key proteins implicated in the formation of plaques and neurofibrillary tangles were correlated with decreased brain levels of PREGS and DHEAS, the authors, in agreement with Brown et al. (27) , supported the concept of a possible neuroprotective role of these neurosteroids in Alzheimer's disease.
Neurosteroids play a role in the excitatory/inhibitory balance in the brain
These neurosteroids, as well as circulating steroids crossing the blood-brain-barrier and penetrating the brain, can influence neuronal functions. Among neurosteroids, allopregnanolone and 3α,5α-tetrahydrodeoxycorticosterone (3α,5α-THDOC) can be oxydized into 5α-dihydroprogesterone or 5α-dihydrodeoxycorticosterone, respectively, which have the ability to bind to the cytosolic progesterone receptor and subsequently activate transcription factors, regulate gene expression, and stimulate protein synthesis (10 -12, 31, 32) . Other neurosteroids bind to membrane-bound receptors to exert rapid, non-genomic effects by binding to or indirectly modulating the activity of neurotransmitter receptors or ion channels. Accordingly, two types of neurosteroids can be differentiated in the brain on the basis of their pharmacological actions: excitatory steroids, which include mainly PREG / S and DHEA / S, the sulphated forms being more active than the free steroid; and inhibitory steroids, which include mainly progesterone and its reduced metabolites 3α/ β,5α/ β-tetrahydroprogesterone, with allopregnanolone presenting the highest brain levels.
The first report of an interaction between neurosteroids and the GABA A receptor is from Harrison and Simmonds (33) and likely corresponded to the Selye's observation in 1941. They demonstrated that alphaxalone increased GABA action when the latter was applied to rat cuneate nucleus slices and enhanced the binding of the GABA A -receptor agonist [ 3 H]muscimol. Extensive electrophysiological studies have been performed, particularly using recombinant GABA A receptors (for a review, see ref. 34 ). Progesterone, its metabolites 3α,5α-tetrahydroprogesterone (allopregnanolone) and 3α,5β-tetrahydroprogesterone (alloepipregnanolone), and 3α,5α-THDOC are potent stereoselective positive allosteric modulators of the GABA A receptor. Patchclamp studies showed that these steroids had no effect on the single-channel conductance of the receptor, but greatly promoted the open state of the GABA-gated ion channel (35) . At physiologically relevant concentrations, that is, below 100 nM, these steroids directly activated the GABA A receptor-channel complex (35, 36) and exerted a GABAmimetic effect sufficient to suppress excitatory neurotransmission (36) . Their effects affect synaptic as well as non-synaptic GABA A receptors and a clear heterogeneity of their interaction with GABA A receptors has been observed, the selectivity depending on individual brain regions and even population of neurons (34) . Therefore, progesterone, allopregnanolone and its stereoisomers, and 3α,5α-THDOC are potent inhibitory neurosteroids. DHEAS has been reported to antagonize the GABA A receptor by interacting with the barbiturate site. In particular, DHEAS decreased the potency of pentobarbital to potentiate the [ 
H]muscimol and [
3 H]flunitrazepam binding to rat brain membranes, primarily by reducing the binding affinities. DHEAS also produced a concentration-dependent blockade of GABA-induced currents in cultured neurons from ventral mesencephalon (38) . DHEAS acts as a non-competitive modulator of the GABA A receptor. Indeed, DHEAS blocked the GABA A receptor in a primary culture of ventral midbrain neurons of fetal rats by accelerating the desensitization and not by acting on the conductance of the chloride channel (39) .
PREGS and DHEAS positively modulate several NMDA-receptor-mediated responses, and thus appear to be excitatory neurosteroids. In the nanomolar range, PREGS specifically enhanced the NMDA-gated currents in spinal cord neurons (40) , intracellular Ca 2+ fluxes mediated through NMDA-receptor channels in cultured rat hippocampal neurons or chick hippocampal neurons (41, 42) , convulsant potency of NMDA in mice (43) , and NMDA-induced phasic firing of vasopressin neurons in the rat supraoptic nucleus (44) . DHEAS potentiated the intracellular Ca 2+ fluxes mediated through NMDA-receptor channels in mouse neocortical neuronal cultures (45) . However, several evidences show that PREGS and DHEAS markedly differ in their effect on the NMDA neurotransmission. PREGS, but not DHEAS, enhanced the NMDA-induced phasic firing of vasopressin neurons in the rat supraoptic nucleus (44) . On the contrary, DHEA / S, but not PREG/ S, potentiated the NMDA-evoked catecholaminergic release (15) and firing activity of CA3 hippocampal neurons (16) . Moreover, the NMDA-stimulated [
3 H]norepinephrine release is inhibited by PREGS (15) . Each neurosteroid thus acts differently on the NMDA receptor complex. PREGS behaves also as a positive modulator of NMDA receptors, whereas epipregnanolone sulphate behaves as a negative modulator by inhibiting NMDA-induced conductances. These two types of steroids act at specific, extracellularly directed sites that are distinct from one another and from the spermine, redox, glycine Mg 2+ , PCP, and arachidonic acid sites (46, 47) . Studies using recombinant receptors showed that the NR2A subunit controls the efficacy of the neurosteroids enhancement, but not inhibition, which suggests in addition that potentiating and inhibitory neurosteroids act at distinct sites on the NMDA receptor (48) . In other respects, there is still no convincing evidence that DHEAS act directly at the NMDA receptor.
Progesterone was reported to attenuate by itself the excitatory neuronal responses to local application of quisqualate, kainite, and NMDA of cerebellar Purkinje cells (49) . It appeared however that two classes of neurosteroids could be distinguished, based on their effects on the NMDA neurotransmission, namely excitatory neurosteroids: PREGS and DHEAS, which potentiate the NMDA-receptor activation through a direct or indirect mechanism, and inhibitory neurosteroids: epipregnanolone sulphate and progesterone, which inhibit the NMDA-receptor activation.
The σ receptor, an atypical neuromodulatory system
The σ receptor represents a unique binding site in mammalian brain and peripheral organs, distinct from any other known transmitter receptors. Historically, the σ receptor was identified by Martin et al. (50) as one of the subtypes of opiate receptors, differentiating in the chronic spinal dog, the unique psychotomimetic effects induced by N-allylnormetazocine (SKF-10,047) (σ-syndrome), from the effects induced by morphine (µ-syndrome) and ketocyclazocine (κ-syndrome). However, subsequent studies established that σ sites possess negligible affinity for naloxone or naltrexone and that certain behaviors elicited by SKF-10,047 were resistant to the blockade by classical opiate receptor antagonists such as naloxone or naltrexone (51) . A complete distinction between the non-opiate σ binding sites and the classical µ-, δ-, and κ-opiate receptors was therefore established (52) . At the same time, σ sites were also demonstrated to be different from the high affinity phencyclidine (PCP) binding sites, located within the ion channel associated with NMDA receptors (52) . The lack of selectivity between the σ and PCP binding sites showed by several compounds, including benzomorphans or PCP derivatives, led to a confusion that was cleared up by the availability of new highly selective drugs. Among them, the reference PCP non-competitive antagonist (+)MK-801 maleate (dizocilpine) fails to displace radioligands labeling the σ sites and selective σ agonists like 1,3-di-O-tolylguanidine (DTG), (+)Ncyclopropylmethyl-N-methyl-1,4-diphenyl-1-ethyl-but-3-en-1-ylamine hydrochloride (JO-1784, igmesine), 2-(4-morpholino)ethyl-1-phenylcyclohexane-1-carboxylate hydrochloride (PRE-084), and 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride (SA4503) do not bind to the NMDA-receptor-associated PCP site. These compounds are now reference compounds in terms of selectivity between σ and PCP receptors.
Multiple criteria are now used to identify σ receptors, especially their ability to bind several chemically unrelated drugs with high affinity. These drugs include psychotomimetic benzomorphans, PCP and derivatives, cocaine and derivatives, amphetamine, certain neuroleptics, many atypical antipsychotic agents, anticonvulsants, cytochrome P450 inhibitors, monoamine oxidase inhibitors, histaminergic receptor ligands, peptides from the neuropeptide Y (NPY) or calcitonin gene-related peptide (CGRP) families, substance P, and neuroactive steroids. The σ binding sites could be labeled by various specific radioligands, including
and [
3 H](+)pentazocine. Pharmacological structure / activity studies led to the definition of two subclasses of σ sites, named σ 1 and σ 2 (53). The two sites were distinguished based on their different drug selectivity patterns and molecular weights. The σ 1 site shows a stereoselectivity with high affinity for the dextrogyre isomers of benzomorphans, whereas σ 2 sites show the reverse stereoselectivity with a lower affinity range (54) . DTG, (+)3-PPP, and haloperidol are non-discriminating ligands with high affinity on both subtypes. In addition, several biochemical features were proposed to be selectively observed with σ 1 receptors such as an allosteric modulation by phenytoin (55) and sensitivity to pertussis toxin or G-protein modulators (56, 57) . The σ 1 receptor is a 29-kDa single polypeptide that has been cloned in several animal species and humans (58 -60) . The ligand binding profile for the cloned σ 1 receptors were similar as described in brain homogenates studies. The 223 amino acid sequence of the purified protein is highly preserved, with 87% -92% identity and 90% -93% homology among tissues and animal species. The protein appeared identical in peripheral tissues and brain and also shares a similarity, 33% identity and 66% homology, with a sterol C 8 -C 7 isomerase (see paragraph 3.1), but no homology was evidenced with any other mammalian protein, outlining the unicity of the σ 1 receptor as compared with any other known receptor. The gene, located on chromosome 9 in human and 2 in rodents, is 7-kbp-long and contains four exons and 3 introns (61). Exon 2 codes for the single transmembrane domain, identified at present, but two other hydrophobic regions exist and one of them may putatively constitute a second transmembrane domain (62) . The σ 1 -receptor sequence contains a 22 amino acid retention signal for the endoplasmic reticulum at its N-terminal region and two short C-terminal hydrophobic amino acid sequences that were suggested to be involved in sterol binding (58) . Amino acid substitutions in the transmembrane domain, S99A, Y103F, and LL105,106AA, did not alter the expression levels of the protein but suppressed ligand binding activity (62) , suggesting that these amino acids belong to the binding site pharmacophore located within the transmembrane domain. In addition, anionic amino acid residues were identified, D126 and E172, that also appeared critical for ligand binding (63) . The promoter region sequence of the σ 1 receptor contains several consensus sequences for the liver-specific transcription factors nuclear factor (NF)-1 / L, activator protein (AP)-1, AP-2, IL-6RE, NF-GMa, NF-GMb, NF-κB, steroid response element, GATA-1, Zeste, and for the xenobiotic responsive factor called the arylhydrocarbon receptor (61, 64) .
The σ 1 protein is widely distributed in peripheral organs, including the heart, lung, kidney, liver, intestines, and sexual and immune glands. In the brain, the σ 1 receptor is expressed in neurons, ependymocytes, oligodendrocytes and Schwan cells (65 -68) . It is particularly concentrated in specific areas throughout limbic systems and brainstem motor structures. The highest levels of σ 1 immunostaining can be observed in the granular layer of the olfactory bulb, hypothalamic nuclei, and pyramidal layers of the hippocampus (25, 65) . Among other areas exhibiting intense to moderate σ 1 immunostaining are the superficial cortical layers, different striatal areas including the caudate putamen and nucleus accumbens core and shell, the midbrain, the motor nuclei of the hindbrain, Purkinje cells in the cerebellum, and the dorsal horn of the spinal cord. At the subcellular level, the σ 1 receptor was found to be mostly present within neuronal perikarya and dendrites, where it is associated with microsomal, plasmic, nuclear, or ER membranes (25, 65) .
The σ 2 site is not yet cloned. It was first characterized in pheochromocytoma PC12 cells (69) . It presents low affinity for (+)benzomorphans and has an apparent molecular weight of 18 to 21 kDa (54). Some selective and high affinity σ 2 site ligands are now available such as 1'-(4- (1-(4-fluorophenyl) (54) , or ibogaine (71) . Several functions have been proposed for σ 2 sites: regulation of motor functions, induction of dystonia after in situ administration in the red nucleus (72) , regulation of ileal function (73) , blockade of tonic potassium channels (74) , potentiation of the neuronal response to NMDA in the CA3 region of the rat dorsal hippocampus (75) , or activation of a novel p53-and caspase-independent apoptotic pathway, distinct from mechanisms used by some DNA-damaging, antineoplastic agents and other apoptotic stimuli (76). (77) . A similar observation was also carried out in primary culture of hippocampal neurons by both (+)SKF-10,047 and (+)pentazocine (78) . After depletion of intracellular Ca 2+ from endoplasmic reticulum (ER) stores, the depolarization-induced increase in [Ca 2+ ] i in the cells could also be modulated by σ 1 agonists. Both effects were blocked by an antisense oligodeoxynucleotide targeting the σ 1 receptor (77). Therefore, activation of the σ 1 receptor resulted in a complex, bipolar modulation of calcium homeostasis. At the ER level, the σ 1 -receptor activation facilitates the mobilization of InsP 3 receptorgated intracellular calcium pools and at the plasma membrane level, the σ 1 -receptor activation modulates extracellular calcium influx through voltage-dependent calcium channels. A co-immunoprecipitation study further revealed that the σ 1 receptor could regulate the coupling of the InsP 3 receptor with the cytoskeleton via an ankyrin B anchor protein, a cytoskeletal protein originally attached to ER membranes (79) . Activation of the σ 1 receptor dissociated ankyrin B from InsP 3 receptor in NG-108 cells, and this dissociation correlated with the efficacy of each ligand in potentiating the Ca 2+ efflux induced by bradykinin. These results, coherent with the σ 1 -receptor subcellular localization (65, 80) , showed that the σ 1 receptor might act as a sensor / modulator for the neuronal intracellular Ca 2+ mobilizations and consecutively for extracellular Ca 2+ influx. After the observation using classical immunoprecipitation and subcellular fractionation techniques that activation of the σ 1 receptor resulted in its translocation from the ER, Hayashi and Su (81 -83) used confocal fluorescence microscopy to examine the protein dynamics in NG108 cells and primary oligodendrocytes over-expressing tagged σ 1 receptors. They observed that endogenously expressed σ 1 receptors localize on the ER reticular network and nuclear envelope. They are seen particularly as highly clustered unique globular structures associated with the ER (80 -82) . These σ 1 -receptor-enriched globules contain moderate amounts of free cholesterol and neutral lipids (81) .
Therefore, on the one hand, σ 1 receptors translocate from the ER lipid droplets to plasmalemma membranes when stimulated by agonists. The translocation of σ 1 receptors, associated with the ankyrin B protein, consequently affects Ca 2+ mobilization at the ER (78, 79) . On the other hand, lipid droplets are formed by coalescence of neutral lipids within the ER membrane bilayer and may, when reaching a critical size, bud off to form cytosolic lipid droplets, serving as a new transport pathway of lipids between the ER and Golgi apparatus or plasma membrane (83 -85) . Indeed, Hayashi and Su (81) observed that when functionally dominant negative σ 1 receptors, which can not target ER lipid droplets and can not translocate, are transfected into NG108 cells, a large amount of neutral lipids and cholesterol is retained in the ER, causing the pathological aggregation of the ER and decreases of cholesterol in the Golgi and plasma membrane. Therefore, σ 1 receptors on the ER may play a role in the compartmentalization of lipids into the ER lipid storage sites and in the export of lipids to peripheries of cells (81) . Lipid rafts play a role in a variety of cellular functions including vesicle transport, receptor clustering and internalization, and coupling of receptor with proteins involved signal transduction (86) . Over-expression of functional σ 1 receptors increased cholesterol contents and altered glycosphingolipid components in lipid rafts of NG108 or PC-12 cells (83, 87) , suggesting that up-regulation of σ 1 receptors potentiates lipid raft formation. Since glycosylated moieties of gangliosides have been proposed to play a role in regulating, for instance, the localization of growth factor receptors in lipid rafts (86) , chronic activation of σ 1 receptors may present substantial consequences in cell viability and differentiation.
2. Neurosteroids and σ drugs apparently share the same binding sites 2.1. Steroids and neurosteroids bind both σ 1 and σ 2 sites in the central nervous system
The initial link between steroids and σ sites was suggested by Su et al. (14) given the discovery that in guinea-pig brain progesterone was the most active inhibitor of [ 3 H](+)SKF-10,047 binding to σ receptors, with a K i value of 268 nM in membrane extracts. It is noteworthy that this K i value is close to the physiological concentration of the steroid during pregnancy. In addition, the variation of the B max for the σ 1 binding site within the rodent brain from 100 (striatum, cingular cortex, globus pallidus) to 600 fmol / mg of tissue (cranial nerve nuclei and cerebellar Purkinje cells) parallels that of progesterone in the rodent brain (for a review, see ref. 72 ). The B max in the presence or absence of progesterone remained between 700 -770 fmol / mg of protein, indicating that all σ 1 sites available could bind the steroid.
Steroids and neurosteroids bind both σ 1 and σ 2 sites in peripheral tissues
Simultaneously with their study in the central nervous system, Su et al. (14) showed that human peripheral blood lymphocytes and rat spleen, ovaries, testis, and pituitary contain high densities of [
3 H](+)SKF-10,047-sensitive σ 1 receptors. The rationale for this outstanding study was based on the observations that gonadal and adrenal steroids share molecular weights, non-peptidic nature, and influence both humoral and cell-mediated immunity with σ-active brain material obtained by partial purification from male guinea pigs. In their binding study performed with crude membrane fractions of rat spleen, Su et al. (14) showed that progesterone was by far the most active inhibitor of [
3 H](+)SKF-10,047 binding to σ receptors, with a K i value of 376 nM in the spleen, a value being close to the physiological concentration of the steroid during pregnancy. The B max in the presence or absence of progesterone remained within the same order of magnitude of that in brain (≈ 600 -800 fmol / mg of protein), indicating that all σ 1 sites available could label the steroid. In addition, Scatchard analysis indicated that the steroid was acting in a competitive manner. Testosterone, desoxycorticosterone, and PREGS were about equipotent, K i values within the micromolar range, while PREG and estrogenic hormones (estriol, estrone and estradiol) remained inactive. The notion that the potent ligands for the progesterone receptor 11β-hydroxy-progesterone, promegestone, and RU-27987 failed to modify Simultaneously with the initial work of Su et al. (14) (88, 89) . In addition, hypophysectomy increased σ binding in the adrenal gland and testis (88) , indicating that in immune and endocrine tissues, the interplay between steroids and σ sites may also exist. Inasmuch as kinetic and pharmacological characteristics of σ receptors were similar to those obtained with steroids in the endocrine and immune systems, it was thus logical to propose that at least some physiological effects of steroids in the endocrine and immune systems might be mediated through σ 1 receptors. Here also, as in the brain and spleen, the rank order for steroids was progesterone > 5α-dihydrotestosterone
Further support for this notion was provided by the observations that ovarian maturing follicules, which are under the control of progesterone, are the richest region for σ sites where hypophysectomy depleted σ binding, indicating the strength of the link between the σ 1 receptor and endocrine tissues. The hypothalamicpituitary-adrenal (HPA) axis may possibly also be under the control of distinct σ-receptor subtypes or distinct intracellular regulations triggered by the same σ-receptor subtype. Evidence for a positive control of the HPA axis by σ drugs was provided by the observations that (±)SKF-10,047, (±)pentazocine, (±)3-PPP, and (±)butaclamol dose-dependently and stereoselectively stimulate adrenocorticotropic hormone release in vivo. In addition, the σ-receptor-mediated modulation of the HPA axis has been demonstrated to be mimicked by steroids, since (+)SKF-10,047 and (+)pentazocine increase, as did progesterone (after estrogen priming), testosterone and desoxycorticosterone, whereas (+)3-PPP and (−)butaclamol decrease prolactin release (90, 91) . This was however not the case in vitro for corticotrophin-releasing-factor-evoked adrenocorticotropic hormone release from primary culture cells of the anterior pituitary (90, 92) .
Splenic lymphocytes and B-enriched lymphocytes possess higher amounts of σ receptors than T-enriched lymphocytes, mesenteric node lymphocytes, or thymocytes (89) . Both (+)pentazocine and DTG have been reported to suppress mitogen (ConA, PWM)-stimulated T-and B-lymphocyte proliferation and LPS-stimulated B-lymphocyte proliferation (88, 89) . More recently, Casellas et al. (93) have shown that SR-31747 inhibits mitogen (ConA, PWM)-stimulated human T-lymphocyte proliferation with a similar efficacy to cyclosporin A; interfere with the production of proinflammatory cytokines IL-1, IL-6, and TNF-α; and also inhibit experimental acute graft-versus-host disease by suppressing the production of IFN-γ by Th1 CD4
+ T-cells (94, 95) . Conversely to most σ drugs, haloperidol affected only the ConA-mediated response, suggesting that σ receptors might differentially regulate T-and Bcell-mediated proliferation. The non-selectivity of both haloperidol and DTG for differentiating σ 1 and σ 2 sites and the discrepant modulation of lymphocyte proliferation induced by haloperidol and DTG do not permit any conclusion to be drawn concerning the subtype of σ receptor involved in both effects. Further assessing the role of σ ligands in the immune system, Ganapathy et al. 3 H](+)pentazocine-sensitive σ 1 sites. This would signify that whatever the phase of the menstrual cycle, the T-cell-mediated impact of progesterone would likely be dependent at least on the σ 1 receptor.
Among peripheral tissues, the liver is the richest tissue in σ binding sites. The concentration of binding protein being appreciatively 20 -100 times higher than that found in the brain, with K d values within the low nanomolar range and B max values ≈ 10 pmol / mg of protein (69, 96 -98) . The similar order of binding potency for σ ligands in inhibiting [
3 H](+)SKF-10,047 binding suggests that central and hepatic σ sites might be identical (72, 99, 100) . However, in liver microsomes, the [ 50 values between 25 and 150 nM), whereas 21-hydroxyprogesterone, 3α-hydroxy-5α-pregnan-20-one, and 17β-estradiol had micromolar affinities. In this latter study, typical σ drugs showed a tendency to attain the uppermost limit at the level of 60% -70% inhibition of the [ 3 H]progesterone binding, whereas progesterone and other steroids increased inhibition in a concentration-dependent manner with 85% inhibition at their maximal concentration used (10 µM). A further step supporting the functional link between steroids and σ receptors concerns the membrane-bound progesterone binding site purified from liver. Most interestingly, Falkenstein et al. (103) Primary breast carcinomas have also been used to assess the putative interrelationship between the σ 1 receptor and human sterol isomerase. Simony-Lafontaine et al. (105) have indeed found a close positive correlation between σ 1 protein expression and progesterone receptor status, but found an inverse one between the σ 1 receptor and human sterol isomerase in 95 patients using immunochemical analysis.
Do neurosteroids bind atypical σ-receptor subtypes?
Using chromatographic procedures designed to purify the σ proteins on a DAPE-containing column, Tsao and Su (106) (58), which was preferentially sensitive to dextrorotary benzomorphans and naloxone but not to DTG or (+)3-PPP and exhibited only high micromolar affinity for progesterone. It is thus tempting to speculate that in the liver but likely also in other tissues, atypical σ proteins might exist with specific binding activity and specific physiological properties.
Apart from the cell surface central benzodiazepineassociated chloride channel and the nuclear glucocorticoid receptor, DHEA binds to both the peripheral benzodiazepine receptor and the σ 1 protein. (98), is that associated with limiting plasma membranes, mitochondria, synaptic vesicles, and endoplasmic reticulum membranes (65) .
In addition, DHEA and its sulphate derivative as well as pregnenolone sulphate have been shown to compete in a concentration-dependent manner with (+)pentazocine for stimulating the [
35 S]GTPγS binding from synaptic membranes from mouse frontal cortex. The notion that this action was mediated by the σ 1 receptor was provided by the following: i) the inhibition of neurosteroid-induced effects by the prototypic σ 1 antagonist NE-100 as well as by progesterone, and ii) the fact that inactivation of G i / o proteins by ADPribosylation with pertussis toxin has prevented this action.
We previously mentioned that Thereafter, Klein and Musacchio (110) ]haloperidol-sensitive σ 1 receptor and the ERG2 binding site were affected by (+)benzomorphans, although (+)pentazocine elicited highly different potencies for both bindings, with K i values being 1.7 nM for the σ 1 site and 1 µM for the ERG2 protein, respectively. It is noteworthy that in mammalian cells, conversely to yeast, sterol signaling is not restricted to the nucleus but also involves the endoplasmic reticulum membrane. This provides further interest to the hypothesis of Moebius and co-workers. A functional complement to this hypothesis was recently provided by Simony-Lafontaine et al. (105) . Indeed, these authors have failed to show any correlation between the expression and the human sterol isomerase from human primary breast carcinomas. They did report however a positive correlation between the σ 1 status and both estrogen and progesterone receptor densities which both correlated negatively with the human sterol isomerase protein. Although the conclusion that the σ 1 receptor represents a sub-form of sterol isomerase still remains in question, it is noteworthy that Hayashi and Su (81 -83) have very recently proposed that the σ 1 protein might take up cholesterol from the intracellular medium to carry it to the plasma membrane and even outside the cell. Steroids have been known for years to activate the HPA axis.
Although (110, 113) have thus proposed that σ binding sites might represent microsomal enzymes related to the cytochrome P450 hemoproteins. They showed that SKF-525A, the classical inhibitor of liver cytochrome P450 oxygenases; l-lobeline, GBR-12909, and sparteine, which exhibit cytochrome P450 inhibitor activities; or cytochrome P450 substrates, such as the β-adrenergic antagonist bufaralol, perhexiline, miconazole, or ajmalicine, displaced [ 3 H]dextromethorphan bindings were not affected by either phenobarbital or phenytoin, known to bind to σ 1 sites (72) and to recruit cytochrome P-450B isoforms, Klein and Musacchio (110) preferred to propose a preferential association of σ proteins with non-B isoforms of the enzymes. Interestingly, haloperidol, the prototypic σ 1 antagonist (114, 115), was acting in human liver microsomes as a competitive inhibitor of 1'-hydroxybufaralol formation with a K i of 1.2 µM, suggesting that the drug was binding to the active site of the enzyme. However, this could not definitively allow the conclusion that σ proteins exhibit enzymatic activity. In this regard, Klein and Musacchio (110) also focused on the purported link between steroids and cytochrome P450 / σ sites. Their attention was stimulated following reports that most steroidogenic enzymes belong to the cytochrome P450 superfamily of oxidases and favored the notion that steroids were active on σ sites rather than on cytochrome P450-related binding proteins. Simultaneously, but conversely to Klein and Musacchio (110) , Yamada et al. (98) , working with liver microsomes, excluded the possibility that cytochrome P450 isoenzymes or other steroid / drug-metabolizing enzymes participate directly in the progesterone / σ binding since they failed to show any correlation between the inhibitory action of the σ drugs as well as that of SKF-525A and GBR-12909 on the binding and oxidative metabolism of liver microsomes. Further support for doubting that σ sites may be solely linked with cytochrome P450 isoenzymes are their distinct cellular distribution since the former but not the latter are close to the plasma and nuclear membranes, as suggested by their sensitivity to 5'-nucleotidase, a plasma membrane marker (116) , their coupling to G proteins (114) , and as shown by both confocal microscopy (80) and electronic microscopy (65) . Altogether, this has ruined the assertion that σ-binding proteins represent cytochrome P450 isoforms or co-factors. Additional interest for the interrelationships between liver and σ-binding proteins has been suggested by the observation that microsomal antiestrogen-binding proteins bound arylethylene-diaminerelated compounds (117) . In fact, microsomal antiestrogen-binding proteins share a high affinity for BD compounds with the emopamil-binding protein. However, the microsomal antiestrogen-binding protein, unlike the emopamil protein, lacks affinity for 17β-estradiol and other estrogens.
Liver and brain mitochondria are known to contain high levels of σ-binding sites as well as steroidogenic enzymes (118) . Although it has long been known that cytochrome P450scc, which converts cholesterol into pregnenolone, is located on the outer membrane of the mitochondria, it is only recently that Klouz et al. (118) have demonstrated that a [ 3 H](+)pentazocine-sensitive σ 1 protein is present on the outer membranes of purified rat liver and brain mitochondria. The analogous distribution of both the steroidogenic precursor enzyme and a σ-binding protein on the outer mitochondrial membrane would be compatible with their interaction, although definitive data are still lacking. The observation that progesterone modulates the mitochondrial binding of [ 3 H](+)pentazocine further strengthens the intimate links between steroids and the σ receptor. The physiological significance of such binding is emphasized by the importance of mitochondria in the regulation of the intracellular calcium homeostasis, the ATP production, as well as the initial phases of the steroid metabolism from cholesterol.
3.2.
Neurosteroids and σ drugs share modulatory functions at both pre-and post-synaptic levels 3.2.1. Do neurosteroids and σ drugs exhibit similar effects on neuronal firing? The initial statement that σ ligands potentiate the NMDA neuronal response originates with Monnet et al. (119, 120) who showed that only drugs active on σ receptors exhibited this ability to affect the NMDAinduced neuronal activation. Therefore, the paradigm of in vivo microiontophoretic application of NMDA and σ 1 drugs has been extensively used in the rat hippocampus to recognize the agonistic or antagonistic profile of action of the ligands. Accordingly, σ drugs that augmented the excitatory action of NMDA were denoted as agonist, whereas those devoid of effect on microiontophoretic application of NMDA but capable of preventing the action of σ agonists, for example, the antipsychotic haloperidol, were denoted as σ antagonists (120). Subsequently, whole-cell patch clamp recordings confirmed these modulatory actions of σ drugs showing that NMDA-induced currents were modified in a similar manner as neuronal firing while non-NMDA responses were only slightly affected by huge doses of the σ drugs (121).
Bergeron et al. (16) extended this observation using the in vivo microiontophoretic approach by showing that DHEA potentiated the NMDA response in a progesterone-, testosterone-, and haloperidol-sensitive manner. However, in this paradigm, neither PREG nor PREGS were acting as σ agonists or antagonists (16, 122) . To further complement their study, Bergeron et al. (16) have also investigated the electrophysiological behavior of σ drugs in spayed rats (i.e., progesteronefree rats). Following a 2 -3-week ovariectomy, the prototypic σ agonist DTG further potentiated the NMDA response in the hippocampal CA3 pyramidal layer. In addition, in pregnant rats and 3-week progesteronetreated rats, the σ 1 agonists were ten times less effective on the NMDA response than in control conditions. Furthermore, at day five post-partum, the neuronal response to NMDA following σ 1 agonist administration was not only restored but again enhanced (123), indicating that σ 1 receptor was most likely tonically inhibited by endogenous progesterone (16, 123) . Altogether, these in vivo data supported the initial statement that progesterone was acting as a σ 1 antagonist (15). Farb et al. (124) , using whole cell recordings from voltageclamped spinal cord neurons, have observed no enhancing effect of DHEAS (at concentrations up to 10 µM) on the basal transmembrane potential, and the spontaneous firing activity and no modulatory effect of DHEAS on the neuronal response to NMDA, that is, a direct modulatory action. However, Meyer et al. (125) showed that DHEAS, in the concentration range of 10 -100 µM, weakly facilitated the activation of CA1 neurons in hippocampal slices after stimulation of the Schaffer collaterals. This enhancement was related however to a concomitant antagonistic activity of the neurosteroid on GABA-mediated inhibitory postsynaptic potentials as well as an indirect augmentation of the glutamatergic excitatory postsynaptic potentials.
PREG and PREGS have no effect on spontaneous firing (124), but allosterically potentiate at micromolar concentrations NMDA-evoked currents in rat hippocampal neurons in culture (see above; and refs. 40 -42, 124, 125) . More recently, Partridge and Valenzuela (126) have shown that PREGS, acting on both NMDA and AMPA ionotropic receptors, enhances paired-pulse facilitation of EPSPs with an EC 50 <1 µM, giving support to the notion that the neurosteroid acts presynaptically to modulate neuronal excitability.
Since the initial studies assessing the intracellular impact of σ drugs on the membrane potential, potassium conductance was considered as the prominent target. Indeed, from rat cortical synaptosomes, C6 glioma cells (74) or NCB-20 cells (127), DTG, (+)3-PPP, and haloperidol have been shown to facilitate hyperpolarization with a reversal potential corresponding to that of K + or to block tonic outward K + currents. In rat neurohypophysis, Wilke et al. (128) have confirmed this notion by providing evidence that (+)pentazocine and (+)SKF-10,047 as well as DTG and haloperidol, but not DHEAS or progesterone, elicited a marked inhibition of K + currents. This latter study then suggested that σ drugs and steroids may act distinctly at the molecular level. Pursuing the elucidation of the molecular target of σ drugs, Soriani et al. (129, 130) have characterized that σ 1 ligands affected at least K + conductance of I A , Ca
2+
-activated K + current, and I M types using perforated patches of frog melanotropic cells. Using reconstituting responses in transfected Xenopus oocytes, Aydar et al. (131) documented that σ 1 receptor, activated by (+)benzomorphans and inactivated by antisense constructs, modulated voltage-gated K + channels (Kv1.4 and Kv1.5) depending on the presence or absence of σ ligands. According to their results, σ 1 protein likely forms a stable complex with the K + channels, acting as a co-allosteric modulatory protein with variable functionalities, depending on the presence or absence of labeling. Interestingly, Wang et al. (132) , using Chinese hamster ovary cells, found that PREGS as well as 3α-hydroxy-5α-pregnan-20-one and 3α-hydroxy-5β-pregnan-20-one increased current amplitude and decreased time constants for the voltage-gated K + channels Kv1.1 and Kv2.1.
Several groups have investigated the neuromodulatory effect of neurosteroids using the intracellular and patch-clamp techniques. Bowlby et al. (133) were the first to demonstrate in outside-out and cell-attached configurations the facilitatory role of PREGS on the NMDA-mediated current from primary culture of rat hippocampal neurons. This action was concentrationdependent and rapidly reversible, supporting a coallosteric modulation (47, 133) . The PREGS-induced increase corresponded to a facilitation of open probability attributed to an increase in both the frequency of opening and mean open time of the NMDA receptor. PREGS was the most active neurosteroid and its effect appeared selective to the NMDA receptor (133) , as soon as the NMDA-subunit NR2A was constitutively or transiently expressed in the cell (48, 134).
Neurosteroids and σ drugs affect neuronal excitability induced by the NMDA receptor
Although the capacity of σ receptor ligands to modulate NMDA-mediated glutamatergic neuronal firing in the mammalian central nervous system has been documented for a decade, the exact nature of this interaction remains still elusive, biochemical paradigms supporting their close interrelationships. In particular, the selective σ ligands igmesine and DTG potentiated and inhibited, respectively, the NMDA response in a concentrationdependent manner, using the in vivo approach combining microiontophoresis and extracellular recordings of hippocampal pyramidal neurons (120) . Haloperidol, which also displays high affinity for σ 1 -binding sites, but not spiperone, another butyrophenone devoid of such affinity, prevented the effects of igmesine and DTG. The ability of progesterone to bind both In addition, progesterone concentration-dependently inhibited (in the 10 nM to 1 µM range) both the potentiation and inhibition of NMDA-evoked release induced by DHEAS and PREGS but also by DTG, respectively. At 100 nM, progesterone decreased the enhancing effect of DHEAS by 69% and abolished the reducing effect of PREGS.
The pre-treatment with pertussis toxin, injected in the dorsal hippocampus 3 to 11 days prior to sacrifice, totally abolished the effects of both DHEAS and PREGS on NMDA-evoked release of [ 3 H]NE, indicating that the neurosteroids were most likely acting via the σ 1 -receptor subtype. From that initial observation, progesterone has been thereafter proposed as a potential endogenous σ 1 -receptor antagonist. Consistently, the σ 1 -receptormediated antagonist-like activity of progesterone has since been supported by in vivo experiments showing that stereotaxically administered, progesterone, inactive on induced neuronal activation in the CA3 dorsal hippocampus, counteracted the DTG-induced facilitation of the response of pyramidal neurons to NMDA (16) . However, in the release experiments, the addition of haloperidol (100 nM) partially reversed the inhibitory effect of PREGS (in the concentration range of 0.1 to 1 µM) on NMDA-evoked [
3 H]NE overflow and induced a robust potentiation of the NMDA response following G i / o protein inactivation. In such conditions, the occurrence of an inhibitory effect of PREGS most likely allows the conclusion that there is an indirect σ 1 -receptor-mediated modulation of the NMDA response since haloperidol and BD1063 blocked the PREGSmediated response. Thus, PREGS would exert two opposite effects on NMDA-induced neuronal activation: the direct potentiation of NMDA-receptor interaction and an indirect σ 1 -receptor-mediated inhibition of the NMDA response, which seems to predominate under physiological conditions. In the light of the data of Farb et al. (124) on isolated neurons, the data obtained in the NMDA-evoked [ 3 H]NE overflow paradigm with hippocampal slices point to an indirect effect of DHEAS on the NMDA response, that is, via the σ 1 -receptor subtype. Although, the affinity of DHEAS for σ 1 -binding sites is within the micromolar range, the effect of BD1063 and haloperidol, which interact with the σ 1 -binding sites but not with the NMDA receptor indicate that DHEAS most likely acted on σ 1 receptors at such nanomolar concentrations depending when the drug application lasted 20 min.
Monnet (135) 
Neurosteroids and σ drugs may have a similar impact on neurotransmitter release
Murray and Gillies (136) have shown that DHEAS, but not PREGS, concentration-dependently (1 pM -10 nM) stimulated endogenous dopamine release from in vitro perfused rat hypothalamic cell cultures. Furthermore, intracerebral microdialysis of PREGS (100 -400 pmol) enhanced in vivo meso-accumbens dopamine release from dopaminergic terminals, and further enhanced morphine-induced dopamine release (137) as well as acetylcholine release from rat hippocampus (138) . Recently, Meyer et al. (139) reported that PREGS (10 -50 µM), DHEAS (0.1 -1 µM) as well as (+)pentazocine (5 -50 µM) caused a robust and transient enhancement of the frequency and amplitude of AMPAmediated miniature excitatory postsynaptic currents in primary mixed hippocampal cell cultures. This effect involved σ-receptor activation per se since haloperidol and BD1063 blocked the PREGS-induced increase in miniature excitatory postsynaptic current frequency. Moreover, the σ 1 -receptor subtype was most likely involved since pre-treatment with pertussis toxin prevented the PREGS response. They also showed with single pre-synaptic elements that the miniature excitatory postsynaptic currents, corresponding to the most elementary forms of synaptic transmission due to postsynaptic responses to action potential-independent spontaneous glutamate release, was sensitive to the modulation of [Ca 2+ ] i with BAPTA-AM, suggesting that neurosteroids as well as σ 1 ligands may interfere with a membrane-bound receptor that initiates a signal transduction cascade involving a desensitization process that occurs simultaneously with the translocation of 
Behavioral effects of σ-receptor ligands and neurosteroids
The neuromodulatory effects of neurosteroids and σ drugs on excitatory and inhibitory neurostransmission have been linked to several physiopathological behavioral responses. In particular, exogenous, systemic as well as central, administration of steroids influences response to stress, depression, anxiety, sleep, epilepsy, and memory formation (6 -13) . Some drugs, including σ ligands and the selective serotonin reuptake inhibitor fluoxetine, were also demonstrated to affect neurotransmission systems by modifying intracerebral neurosteroid levels (140, 141) . Systemic administration of selective σ 1 -receptor agonists and antagonists has also notable effects on response to stress, depression, anxiety, drug addiction and memory formation. A crossed pharmacology between both systems was clearly evidenced, reinforcing the concept that an interaction with the σ 1 receptor is a main component in the rapid neuromodulatory effect of neurosteroids. We will focus more specifically on two behavioral aspects, learning and memory and drug addiction, which are particularly representative of the recent achievements in the field. The reader is encouraged to refer to recent and exhaustive reviews covering similar aspects relevant to depression and mood disorders (142, 143).
Neurosteroids and σ drugs affect learning and memory processes 4.1.1. Pro-mnesic effects of neurosteroids and σ drugs
The involvement of neurosteroids in learning and memory processes has been demonstrated, first, by the observation of pro-mnesic and anti-amnesic effects of exogenously administered neuroactive steroids and, second, by a parallel decrement between cognitive functions and neurosteroid levels during normal and pathological aging. Neurosteroids have been shown to affect memory performances by themselves in control animals and to alleviate the deficits in several pharmacological models of amnesia. For instance, DHEA, PREG, and their sulphate esters enhanced, after central administration, memory retention in an active avoidance learning task in mice after central or oral administration (144 -146) . PREGS appeared as the most potent compound and its long-duration effect suggested that PREG may serve as a precursor for the formation of other different steroids, ensuring a near-optimal modulation of transcription of immediate-early genes required for the facilitation of the plastic changes in memory processes (145) . PREGS also enhanced memory formation when administered after the first training session in an alternation task in rats (147) or in an appetitive reinforced Go -No go visual discrimination task in mice (148) . The rapid effect of the sulphated steroid clearly evokes its non-genomic interaction with both the GABA A and / or NMDA receptors and suggests that the learning-induced activation of physiological responses could be enhanced by an increase in neuroactive steroid levels. PREGS also enhanced performances in a spatial recognition memory task after post-acquisition intracerebroventricular infusion (138) . Interestingly the active dose, 12 nmol, induced a mild increase in extracellular acetylcholine (ACh) level measured by microdialysis, whereas higher doses (up to 192 nmol) provoked robust increases in ACh levels without behavioral improvement. DHEAS, administered immediately after training systemically or centrally or given in the drinking water during two weeks, facilitated memory retention in a step-down passive avoidance test in mice but did not improve acquisition (149) . Moreover, when administered subcutaneously or intracerebroventricularly, the steroid improved the percentage of correct responses in a delayed alternation task in a Y maze and improved the performances in a water-maze task as compared to vehicle (oil)-treated rats (150) . Therefore, memory enhancing effects have been demonstrated for both PREGS and DHEAS.
In most of the studies examining the anti-amnesic potentials of σ 1 -receptor agonists in either pharmacological or pathological models of amnesia, a putative pro-mnesic effect was examined in short-term or longterm memory tests, by injecting the drugs alone. Consistently, none of the compounds, (+)SKF-10,047, (+)pentazocine, PRE-084, igmesine, SA4503 or DTG, tested in large dose range, facilitated learning in control animals (for reviews, see refs. 6 -8) . Activation of the σ 1 receptor failed to improve learning capacities in control animals. Conversely, σ 1 antagonists such as
failed to show any amnesic effect. Moreover, downregulation of the σ 1 -receptor expression using in vivo antisense strategies also failed to affect the learning ability of mouse submitted to a passive avoidance test, confirming the lack of involvement of the receptor in normal memory functions (151, 152) . The behavioral phenotyping of σ 1 -receptor knockout animals (153) is expected to confirm this observation. The lack of consequence of σ 1 -receptors blockade on learning processes is presently understood as a consequence of its neuromodulatory role. As usually observed in most of the physiological or pharmacological tests used to evidence the σ 1 -receptor pharmacology, σ 1 compounds are devoid of effect alone, but exert some action only when the transmission is perturbed. Therefore, the direct effects of neurosteroids on learning capacities may not exclusively involve their interaction with the σ 1 receptor, but also imply their modulatory actions at GABA A and NMDA receptors. Indeed, both receptors are expressed on cholinergic neurons of the medial septum and diagonal band projecting into the hippocampal formation and glutamatergic and GABAergic responses regulate the activity level of cholinergic inter-neurons. Cholinergic systems sustain the learning-induced plasticity and cholinergic deficiency, particularly during neurodegenerative diseases, is directly responsible for learning deficits (24) . Therefore, the cholinergic activity of neurosteroids, shown on physiological studies (138) , is directly responsible for their anti-amnesic properties (12, 13).
Anti-amnesic effects in cholinergic models of amnesia
The beneficial effects of neuroactive steroids were tested in experimental models of amnesia. Several studies examined the effects of steroids on amnesia induced in rodents by the cholinergic muscarinic antagonist scopolamine. PREGS and DHEAS reversed its amnesic effects in mice submitted to a foot-shock active avoidance test (149), step-through type passive avoidance test (154) , Go -No go visual discrimination task (148) , and spontaneous alternation and place learning in a water-maze (155). The beneficial effects induced by both sulphated steroids could be related to their acetylcholine release properties resulting from negative modulation of GABA A receptors and/ or positive modulation of NMDA receptors. However, an involvement of the σ 1 receptor could not be definitively excluded. The learning impairment induced by scopolamine, measured using spontaneous alternation, passive avoidance, or water-maze procedures, could be attenuated or reversed by σ 1 agonists. This was indeed described for DTG, (+)3-PPP, (+)SKF-10,047, pentazocine, igmesine, or SA4503 (155 -160). These effects could be fully blocked by σ 1 antagonists or an in vivo antisense strategy (152) . In addition, administration of SA4503 has also been reported to attenuate the learning impairment in rats with cortical cholinergic dysfunction, such as ibotenic acid injection of the basal forebrain, that is, lesioning cholinergic ascending pathways, in the passive avoidance and water-maze tests (161) . In parallel, physiological studies showed that (+)SKF-10,047, pentazocine, DTG, igmesine or SA4503 potentiated [
3 H]acetylcholine release from hippocampal slices in vitro or extracellular acetylcholine levels, measured in vivo by microdialysis, in the rat frontal cortex and hippocampus (162 -164) . Therefore, activation of the σ 1 receptor either directly affects cholinergic systems or, through a positive modulation of the NMDA-receptor activation, indirectly potentiates acetylcholine release. At the behavioral level, a crossed pharmacology between neurosteroids and σ 1 -receptor ligands was reported for this amnesia model. DHEAS and PREGS attenuated the the scopolamine-induced learning impairments in mice submitted to a series of spatial and contextual tests. These effects could be blocked by the selective σ 1 -eceptor antagonist NE-100 or progesterone (155). Similar crossed pharmacology studies have been performed in amnesia models induced by blockade of the NMDA-receptor activation.
Anti-amnesic effects in NMDA-receptor-dependent amnesia
Impairment of the NMDA-receptor activation, by either competitive or non-competitive antagonists, also results in marked learning deficits. Administration of PREGS dose-dependently reduced the learning deficit and motor impairment induced by pre-training administration of the competitive antagonist 3-((±)2-carboxypiperazin-4-yl)-propyl-1 phosphonic acid (CPP) in a step-through passive avoidance task in the rat (165) or induced by (−)-2-amino-5-phosphonopentanoic acid (D-AP5) in an active avoidance test in mice (166) . In addition, administration of PREGS in rats prevented the cognition deficits induced by dizocilpine, a noncompetitive NMDA-receptor antagonist (167) .
The σ 1 -receptor agonists were extensively studied in this last amnesia model. (+)SKF-10,047, (+)pentazocine, igmesine, DTG, PRE-084, or SA4503 attenuated the dizocilpine-induced learning deficits in rats and mice submitted to mnesic tasks involving spontaneous alternation, passive avoidance, place learning in the water-maze, three panel runway, or 8-radial arms maze (160, 168 -171) . Moreover, the involvement of the σ 1 receptor in the anti-amnesic effect induced by the steroids was indicated by the blockade of both DHEA sulphate and pregnenolone sulphate effects by the selective σ 1 -receptor antagonists BMY-14,802 and NE-100 (17, 172) and the observation that progesterone behaved as a clear antagonist of the efficacy of the σ 1 agonists (17, 172) .
Interestingly, the in vivo antisense strategy revealed some discrepancies regarding the anti-amnesic effects mediated by neurosteroids. The antisense probe treatment led to a complete blockade of the anti-amnesic effect mediated by DHEAS, confirming that the antiamnesic effect of the steroid involves primarily an interaction with σ 1 receptors. On the contrary, PREGS still induced a potent anti-amnesic effect in antisensetreated animals. This result must be analyzed in line with other observations. Both steroids act as negative allosteric modulators of the GABA A -receptor-mediated responses (37, 173, 174) . They also potentiate several responses mediated through the NMDA receptor. However, when PREGS acts through a specific extracellularly directed modulatory site located on the NMDA-receptor complex, but distinct from either the spermine, glycine, phencyclidine, arachidonic acid, Mg 2+ or redox sites (47) , DHEAS failed to affect the NMDA receptor through a direct interaction (46, 175) . However, through its interaction with the σ 1 receptor, DHEA/ S have been reported to indirectly potentiate several NMDA-mediated physiologic responses in vitro and in vivo, and at the behavioral level (15, 16, 155, 160, 176) . Morever, PREGS acts as an inverse σ 1 -receptor agonist in vitro, when DHEA / S is a full agonist (see above, and ref. 15 ). Parallel to this observation, it must be noted that both steroids differently affected the extent of excitotoxic insults resulting from over-activation of the NMDA receptor. PREGS was reported to facilitate the NMDA-receptor-mediated excitotoxic cell death in several in vitro models of neurodegeneration (177) and in mice exposed to a hypoxic insult in vivo (178) . The selective and efficient potentiation of the NMDAreceptor activation induced by PREGS led to major consequences in the case of over-activation of this receptor. Indeed, the steroid potentiated the excitotoxic neurodegeneration and worsened the resulting behavioral deficits. DHEAS, on the contrary, prevented or reduced the neurotoxic effects in primary hippocampal cultures exposed to NMDA (175, 179, 180) and blocked both the appearance of neurodegeneration and the resulting learning deficits in mice exposed to carbon monoxide (178) . This neuroprotective effect seemed only partly related to the interaction of the steroid with the σ 1 receptor, since it was poorly sensitive to σ 1 antagonists, NE-100, rimcazole, or BD1063 (178, 179) . However, these different results confirmed and brought physiopathological consequences for the differential pharmacological profiles presented by both steroids.
Anti-amnesic effects of neurosteroids and σ drugs during aging
Finally, the anti-amnesic effects of neuroactive steroids and σ 1 -receptor agonists have been tested against learning deficits induced by normal or pathological aging. Robel et al. (181) observed a significant correlation between the PREGS levels in the hippocampus of aged rats and memory performances in a water-maze and a two-trial recognition task; the animals with better performances had greater levels of PREGS. Furthermore, Vallée et al. (24) reported significant and selective decreases of hippocampal PREGS levels in aged rats as compared with young adults, and a positive correlation between these levels and cognitive performances in a delayed alternation task in the Y-maze and a place learning task in the water-maze. Administration of PREGS directly into the hippocampus temporarily corrected the memory deficits of aged rats when administered immediately after the acquisition trial (24) . Cholinergic systems in the basal forebrain are known to be altered during aging and degenerative changes in cholinergic nuclei are correlated with memory impairment in aged rats. The central administration of PREGS stimulated acetylcholine release in the adult rat hippocampus. Moreover, a correlation between PREGS levels and learning and memory performance was evidenced in 24-month-old rats (24) . In parallel, a single systemic injection of DHEAS immediately after training improved the impairment of memory in middle-aged and old mice submitted to a footshock active avoidance test, up to the levels observed in young mice (149) . Furthermore, the neurosteroid plays a physiological role in preserving and / or enhancing cognitive abilities in old animals, possibly via an interaction with the central cholinergic systems. Such observations suggest that the neuromodulatory action of PREGS and / or DHEAS reinforce tonically neurotransmitter systems. Furthermore, since their blood concentrations decrease with age, neurosteroids might be the rate-limiting endogenous substances for correct memory capacities (182) .
The σ 1 -receptor expression and behavioral efficacy of selective σ 1 drugs has been extensively studied in aged animals. Using radioligand binding, positon-emission tomography (PET) scan imaging, and immunohistochemical and molecular approaches, a remarkable preservation of the σ 1 -receptor expression levels has been observed in the different brain structures, including limbic and cortical structures of SAM, aged mice or aged monkeys (25, 26, 183, 184) . In parallel, σ 1 -receptor agonists attenuated after both acute and repeated treatments, the learning deficits in SAM, aged mice or aged rats (25, 176, 185, 186) . Decrease of central levels of neurosteroids was identified in these studies. Moreover, a preserved expression of σ 1 receptors was documented by RT-PCR and immunohistochemical techniques in numerous brain structures, whereas the behavioral efficacy of σ 1 drugs was maintained and inversely correlated with the decrease in progesterone contents (25, 26) . Although no direct link could be formalized, these observations are in agreement with the endocrine manipulations studies detailed in paragraph 4.3.
Neurosteroids and σ drugs may influence abused drug intake
The recent demonstration by Romieu et al. (187) that neuroactive steroids are able to modulate the acquisition of cocaine-induced conditioned place preference (CPP), a behavioral procedure measuring the appetitive properties of drugs, suggest their influence on acquisition of drug addiction. PREGS and DHEAS potentiated cocaine-induced CPP acquisition, as do selective σ 1 -receptor agonists, like igmesine or PRE-084, and the effect was blocked by the σ 1 antagonist BD1047 (188) . Exogenous administration of progesterone, or its endogenous accumulation by a finasteride treatment, blocked the cocaine rewarding effect (187) . This may be mediated through either GABA A -and NMDA-receptormodulation, since mesolimbic dopamine neurons in the nucleus accumbens are under the control of inhibitory GABA neurons and excitatory glutamatergic neurons originating from the frontal cortex or hippocampus. Indeed, diazepam, a benzodiazepine acting as a positive GABA A -receptor modulator, reduced the release of dopamine in the nucleus accumbens measured by in vivo microdialysis (189) and, in turn, attenuated cocaine-induced CPP (190) . Similarly, pre-synaptic NMDA receptors facilitate dopamine release and NMDA-receptor antagonists decreased cocaine-induced locomotor stimulation, sensitization, or CPP (191, 192) . Since the respective pharmacological profiles of DHEA, PREG, and progesterone on GABA A and NMDA receptors are highly consistent with such actions, these interactions could be involved in their effects on cocaine-induced CPP. However, most of GABA A -and NMDA-receptor modulators showed CPP or place aversion (CPA) by themselves. Indeed, CPP was observed with the direct GABA A agonist meprobamate, the GABA metabolite γ-hydroxybutyric acid (GHB), or several benzodiazepine compounds. Moreover, benzodiazepine antagonists or inverse agonists produced CPA (for an exhaustive review, see ref. 194) . It is noteworthy that 3α-hydroxy-5α-pregnan-20-one (allopregnanolone), devoid of affinity for the σ 1 receptor but acting as a highly efficient GABA A -receptor positive modulator induced CPP after exogenous administration (193) . While NMDA-receptor competitive antagonists have also been reported to induce CPP, more inconsistent results were reported with noncompetitive antagonists, particularly dizocilpine and both CPP or CPA has been described (194) . Curiously, neuroactive steroids failed to induce CPP or CPA alone, with the notable exception of testosterone (195) .
Interestingly, a recent report by Barrot et al. (137) showed that intracerebroventricular injection of PREGS increased dopamine efflux measured in the rat nucleus accumbens by in vivo microdialysis and potentiated the morphine-induced dopamine release. Consequently, the authors suggested that this potentiation of mesolimbic dopamine concentration may explain the involvement of neurosteroids in mood and motivation.
The involvement of the σ 1 receptor in several cocaineinduced behavioral effects has also been extensively examined (for a review, see ref . 196) . Selective σ 1 antagonists, like haloperidol, BMY-14,802 or rimcazole, blocked the locomotor stimulant effect of cocaine after acute administration (197 -199) and the development of behavioral sensitization after repeated cocaine injections and withdrawal (200) . Selective σ 1 antagonists, like BD1047 or NE100, or antisense oligodeoxynucleotide probes targeting the σ 1 receptor also blocked acquisition or expression of cocaine-induced CPP in mice (188, 201) .
It is noteworthy that the modulating effect of neurosteroids was less observable on cocaine-induced locomotor sensitization and toxicity. Some effects could however be observed on locomotor sensitization such as DHEA sensitizing to a delayed injection of cocaine and progesterone attenuating the short-term sensitization to cocaine (P. Romieu & T. Maurice, unpublished observations). However, σ 1 antagonists potently prevented cocaine-induced locomotor stimulation and sensitization (197, 200) and contribution of the other targets of neurosteroids, namely, the NMDA and GABA A receptors, but also of genomic effects may also contribute to an effective modulation of locomotor effects. Observation of a clear pharmacological response on reward as compared to other behavioral responses suggests that the σ 1 receptor and the resulting interaction of neuroactive steroids appear to be particularly sensitive in specific brain structures and pathways. Indeed, a 4-day cocaine treatment resulted in high increase of the σ 1 -receptor mRNA levels only in the nucleus accumbens, a key structure for drug reward (188) , while self-administered methamphetamine increased expression of σ 1 -receptor mRNA in the hippocampus and decreased its expression in the frontal cortex, in contrast to yoked administration (202) .
A recent study extended the behavioral evidences by showing that neurosteroids, administered at very low doses also modulate cocaine's effects. A modified passive avoidance procedure was used in mice to examine whether cocaine induces state-dependent learning (StD) (203) . Cocaine administration, at the low dose of 0.1 mg / kg before training, produced a chemical state in the brain that served as an endogenous cue. Animals must be treated with the same dose of the drug before retention to ensure optimal retention. Among neuroactive steroids, pregnanolone and allopregnanolone sustained StD by themselves. However, steroids also acting as σ 1 agonists (e.g, DHEA and PREG) or as antagonist (i.e., progesterone) failed to induce StD but modified the cocaine state. The σ 1 agonist igmesine or antagonist BD1047 also failed to induce StD but modified the cocaine state. Furthermore, optimal retention was noted in mice trained with (igmesine or DHEA) + cocaine and tested with a higher dose of cocaine or in mice trained with (BD1047 or progesterone) + cocaine and tested with vehicle. From these studies, it is concluded that a low dose of cocaine induces a chemical state/ memory trace that sustains StD. Modulation of σ 1 -receptor activation is not sufficient to provoke StD, but it alters the cocaine state, in line with the pure neuromodulatory role of the σ 1 receptor. Neurosteroids have a unique impact on statedependent versus state-independent learning, via GABA A -or σ 1 -receptor modulation, and can affect the cocaine-induced mnesic trace at low brain concentrations.
Finally, similar observations could be presented for other drugs of abuse, since methamphetamine, morphine, and ethanol also involve σ 1 -receptor activation (202, 204 -206) . In particular, morphine-induced hyperlocomotion and CPP could be modulated by σ 1 -receptor ligands (T. Maurice, unpublished observations). Moreover, the naloxone-precipitated morphine withdrawal symptoms could be blocked by administration of the σ 1 agonist igmesine (T. Maurice, unpublished observations) as well as DHEA in a NE-100-sensitive manner, thus confirming the involvement of the σ 1 -receptor subtype, as stated by Ren et al. (207) .
Cross-influences between neurosteroids and σ receptor
The interaction of endogenous neuro(active)steroids with the σ 1 receptor has direct physiological consequences. The variations of neuro(active)steroids levels, for example, during pregnancy, stress, mood disorders, or normal or pathological ageing, directly affects the efficacy of σ 1 -receptor agonists in vivo.
The direct demonstration of the physiological importance of the steroidal tonus was provided by Bergeron and co-workers (123) who examined the effects of σ 1 agonists in control female rats, at day 18 of pregnancy and day 5 post-partum, and in ovariectomized rats following a 3-week treatment with a high dose of progesterone. In pregnant rats and following a 3-week treatment with progesterone, tenfold higher doses of DTG, (+)-pentazocine, and DHEA were required to elicit a potentiation of the NMDA response of hippocampal neurons comparable to that obtained in control females. Conversely, at day 5 post-partum and following a 3-week treatment with progesterone and after a 5-day washout, the potentiation of the NMDA response induced by the σ agonist DTG was greater than in control females (123) . These data showed changes in the function of σ 1 receptors during pregnancy and postpartum, that is, in case of drastic variations of steroid levels, and suggested that the steroid tonus may impede the behavioral efficacy of σ 1 agonists.
This question was also addressed through a series of endocrine manipulations using adrenalectomized (AdX) and castrated (CX) mice, to deplete the peripheral biosyntheses in circulating steroids, and treated with trilostane or finasteride, in order to deplete or accumulate progesterone in the brain. Accordingly, the in vivo [ 3 H](+)SKF-10,047 binding levels to σ 1 sites in the mouse forebrain and hippocampal formation appeared significantly increased in AdX/ CX mice and further increased after the trilostane treatment. Conversely, the finasteride treatment led to a significant decrease of binding as compared to AdX / CX animals. The attenuating effect of PRE-084 against dizocilpine-induced learning impairment was examined using spontaneous alternation behavior, step-down passive avoidance, and contextual latent learning in the elevated plus-maze in the different endocrine conditions. The learning deficits induced by dizocilpine were not affected by the treatments. The anti-amnesic effect of PRE-084 was facilitated in AdX/ CX mice and even more after trilostane treatment since several parameters for (PRE-084 + dizocilpine)-treated animals returned to control values. The PRE-084 effect was blocked after finasteride (208) . Moreover, PREGS infusion in AdX / CX rats was previously reported to prevent the learning deficits induced by dizocilpine and (−)3-[2-carboxypiperazin-4-yl]-propyl-1-phosphonic acid (CPPene) (209) . It was also demonstrated that infusion of PREGS markedly increased the brain contents of PREG, progesterone, 5α-pregnane-3,20-dione, and allopregnanolone (209) . Interestingly, blockade of 5α-reductase activity led to the disappearance of the PREGS effect, leading the authors to suggest that an increase in allopregnanolone level could mediate the observed effect. As an alternative, 5α-reductase activity inhibition led to sustained increase in progesterone levels and the steroid, acting as a σ 1 -receptor antagonist, which may attenuate the PREGS effect.
We also observed that an acute swim stress induced an increase in the level of progesterone and a decrease of in vivo [
3 H](+)-SKF-10,047 binding in the hippocampus of control animals (21) . These effects were enhanced in AdX/ CX mice, but completely blocked following treatment with trilostane. A significant inverse correlation was observed between progesterone increase and the inhibition of in vivo binding to σ 1 sites after stress among the different endocrine conditions. These observations not only confirmed that neurosteroids modulate the efficacy of σ 1 -receptor agonists in the response to stress and depression, but also showed that endogenous neurosteroid levels directly and tonically regulate the in vivo bioavailability of σ 1 receptors.
These observations documented that progesterone could be a major endogenous effector of the σ 1 receptor and stressed that physiopathological variations of this neurohormone must be taken into consideration before designing any pharmacological strategy targeting the σ 1 receptor. Moreover, a different behavioral efficacy of σ 1 -receptor ligands was observed among mouse strains, that could be related to the endogenous tonus in neurosteroids (210) . In particular, the C57BL / 6 mouse appears to present the lowest progesterone levels in basal and stressful conditions, in line with a higher efficacy of σ 1 drugs and a highest vulnerability to cocaine's appetitive effects (210) . Extrapolated to humans, patient populations showing important levels in steroids acting negatively on σ 1 receptors may impede the use of selective σ 1 ligands.
On the contrary, physiopathological conditions with disturbed steroidal tonus may be highly sensitive to σ 1 -ligand treatments. This is of importance during ageing and in Alzheimer's disease-like neurodegenerative pathologies. With this regard, we examined the pharmacological efficacy of several σ 1 -receptor agonists in two nontransgenic rodent models of Alzheimer's disease: mice injected acutely and intracerebroventricularly with β 25-35 -amyloid peptide (28) and rats infused intracerebroventricularly during 14 days with the β 1-40 -amyloid protein delivered using an Alzet minipump (29) . Neurosteroid levels were measured in several brain structures after β-amyloid injection in mice or infusion in rats, in basal and stress conditions. The β 25-35 mice exhibited decreased progesterone levels in the hippocampus. Progesterone levels, both under basal and stress-induced conditions, were also decreased in the hippocampus and cortex of β 1-40 -amyloid-treated rats. The levels in PREG / S and DHEA/ S appeared less affected by the β-amyloid infusion (29) . The behavioral efficacy of σ 1 agonists is known to depend on the levels of neuro(active)steroids synthesized by glial cells and neurons, which are affected by the β-amyloid toxicity. The antidepressant-like response of animals was examined using either the forced swim test in mice or the conditioned fear stress test in rats. The β 25-35 -peptideinjected mice developed memory deficits after 8 days in contrast to the controls injected with scrambled β [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] peptide or vehicle solution. In the forced swim test, the β-amyloid treatment failed to affect the immobility duration, but the antidepressant effect of the σ 1 agonists was facilitated in β 25-35 -treated mice: igmesine reduced immobility duration at 30 mg / kg versus 60 mg / kg in control groups and PRE-084 decreased immobility duration at 30 and 60 mg / kg only in β 25-35 -treated mice. In comparison, desipramine reduced the immobility duration similarly among the groups and fluoxetine appeared less potent in β 25-35 -treated animals (28) . In rats, igmesine and (+)-SKF-10,047 significantly reduced the stress-induced motor suppression at 30 and 6 mg / kg, respectively, in β 40-1 -amyloid-treated control rats. Active doses were decreased to 10 and 3 mg / kg, respectively, in β 1-40 -amyloid-treated rats. The DHEAS effect was also facilitated, both in dose (10 vs 30 mg / kg) and intensity, in β 1-40 -amyloid-treated rats (29) . These results suggested that σ 1 -receptor agonists, due to their enhanced efficacy in a nontransgenic animal model, may be particularly interesting drugs to alleviate not only Alzheimer's disease-associated memory impairments but also depressive symptoms (8, 28, 29, 176, 185) .
Conclusions
The understanding of the action of steroids within the brain functions and their inter-relationships must be currently considered within the double framework of endocrine mechanisms, as responses elicited by hormones secreted by the gonads and adrenal glands, and regulation of neural functions by autocrine and / or paracrine actions of neurosteroids, that is, as responses elicited by steroids synthesized and metabolized within the nervous system. Whatever their origins, several lines of evidence support the notion that apart from their genomic actions, neuroactive steroids, as well as neurosteroids, play a pivotal role in cognition and adaptive responses to neuronal damage. Moreover, the σ 1 receptor constitutes one of the key targets in their trophic, neuromodulatory and behavioral effects. Although partially unveiled using pharmacological, biochemical, and genetic approaches, experiments outlined above have hence enlightened and documented the role of this orphan endoplasmic reticulum-bound receptor in the regulation of physiologic responses. These include modulation of transmembrane K + and Ca 2+ fluxes, NMDA-sensitive glutamatergic, catecholaminergic, and cholinergic pathways, to the immediate and robust recruitment of Ca 2+ -dependent intracellular signaling and protein (de)phosphorylation. These neuromodulatory effects accounted for the molecular mechanisms of interaction between σ 1 sites and neuro(active)steroids in relationship with most of their physiological properties, detailed here in terms of cognitive and addictive outcomes. The merely simultaneous impact of σ 1 -receptor activation at the level of both cytosol and nuclear and plasmic membranes, due to its unique translocation process, provides further insight into the identification of the commonality of action of σ 1 drugs / neurosteroids involved in these behavioral tests and further points out the interest for the σ 1 receptor in cognition and ageing. This should facilitate the elaboration of efficient strategies for preventing and treating cognitive and memory deficits during ageing, stimulating neural regeneration and correcting behavioral disorders in response to stress. These above-mentioned findings support the notion that the recruitment of membranebound second messenger cascades (i.e., G-protein / PLC / PKC pathway) via activation of a single transmembrane domain intracellular receptor constitutes a novel mode of action for medicines.
Finally, behavioral studies focusing on the impact of variations in the central level of neurosteroids in AdX/ CX mice demonstrated that progesterone levels in basal and stressful conditions determine the behavioral efficacy of σ 1 -receptor drugs. Endocrine conditions must therefore be taken into consideration for the development of σ 1 -receptor-based therapies. Extrapolated to humans, patient populations showing important levels in steroids acting negatively on σ 1 receptors may impede the use of selective σ 1 ligands. On the contrary, physiopathological conditions with disturbed steroidal tonus may be particularly responding to σ 1 ligand treatments.
Indeed, σ 1 -receptor-based therapies were already proposed to be of physiological and therapeutic importance in neurology and psychiatry since the σ 1 receptor is abundant in the brain, where it regulates these functions. Although this σ 1 receptor plays a crucial role in the adaptative changes mandatory for memory processes or addiction, it remains however to determine whether and how these molecular mechanisms involved in learning and recruited by σ 1 drugs operate synergically (most of them usually proceeding in parallel) and whether the interplay between cytosolic and membrane-bound molecular events occurring in response to σ 1 drugs is consistent with the roles of cytoskeleton in mediating these changes. There is no doubt that the identification of the nature of the proteins synthesized in response to σ 1 drugs will also need to be addressed soon.
